While several molecular markers that are used to evaluate the development and prognosis of bladder cancer have been studied, the limited value of these established markers has created the need for ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

In addition, the proportion of muscle-invasive bladder cancer was limited and ... value in locally advanced invasive or metastatic urothelial cancer.

Opens in a new tab or window The indication for sacituzumab govitecan (Trodelvy) in previously treated patients with locally advanced or metastatic urothelial cancer was withdrawn last month after ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

The U.S. Food and Drug Administration had granted accelerated approval to Trodelvy for previously treated patients with metastatic urothelial ... with advanced bladder cancer in the trial.

This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a ...

to treat a subset of bladder cancer patients. The drug has been approved as an oral monotherapy for adults with unresectable ...

to be used as a monotherapy in treating adults with unresectable or metastatic urothelial carcinoma (UC), which is the most common form of bladder cancer (1,2). This approved indication specifically ...